US generics lobby the Association for Accessible Medicines (AAM) has welcomed passage of Q1/Q2 provisions in recent US ...

A group of 42 US states and territories has filed a fresh antitrust lawsuit accusing Swiss pharma Novartis (NOVN: VX) and its former generics unit Sandoz (SIX: SDZ) of colluding to fix prices and ...

Market research group DelveInsight suggests the market for TIGIT inhibitors could expand sharply over the next decade, even ...

US biotech major Amgen announced financial results for the fourth quarter and full year of 2025 after markets closed on ...

Japanese drugmaker Astellas Pharma has announced top-line results from the STARLIGHT 2 Phase III pivotal study for ...

The US Department of Health and Human Services (HHS) has sharply expanded its use of artificial intelligence, listing around 450 AI use cases across the department in a newly published fiscal 2025 ...

UK biotech Levicept, which is focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announced the appointment of James Sandy as chief development officer ...

British drugmaker GSK (LSE: GSK) reported higher revenue and earnings for both the fourth quarter and full year, reflecting strong demand for HIV and specialty medicines. Fourth-quarter revenue rose 6 ...

US pharma giant Merck & Co (NYSE: MRK) has announced financial results for the fourth quarter and full year of 2025. Merck’s ...

US pharma giant Pfizer today announced positive top-line results from the Phase IIb VESPER-3 study investigating monthly ...

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...

Danish drugmaker Novo Nordisk has announced headline results from REIMAGINE 2, a Phase III study from the global REIMAGINE clinical trial program.